Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics IncfiledCriticalPearl Therapeutics Inc
Priority to CR20130589ApriorityCriticalpatent/CR20130589A/en
Publication of CR20130589ApublicationCriticalpatent/CR20130589A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Se proporcionan composiciones, métodos y sistemas para la administración pulmonar o nasal de dos o más agentes activos a través de un inhalador de dosis medida. En una forma de realización, las composiciones incluyen un medio de suspensión, partículas de agente activo, y partículas en suspensión, en la que las partículas de agente activo y partículas de suspensión forman una co-suspensión en el medio de suspensión.Compositions, methods and systems for pulmonary or nasal administration of two or more active agents are provided through a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspended particles, in which the active agent particles and suspension particles form a co-suspension in the suspension medium.
CR20130589A2013-11-132013-11-13
COMPOSITIONS, METHODS AND SYSTEMS FOR ADMINISTRATION / RESPIRATORY SUPPLY OF TWO OR MORE ACTIVE AGENTS
CR20130589A
(en)
Pharmaceutical composition for inhalation comprising aclidinium, with lactose, which provides a dose of 322 ug of free base and approx. 140 ug of aclidinium bromide; a method to treat a respiratory condition selected from asthma and epoc; use of the composition; and a calibrated dry powder inhaler device comprising it